Learn More
PURPOSE We conducted a phase I trial of the injectable formulation of topotecan given orally once daily for 5 days for 2 consecutive weeks (qd x 5 x 2) in pediatric patients with refractory solid tumors. PATIENTS AND METHODS Cohorts of two to six patients received oral topotecan at 0.8, 1.1, 1.4, 1.8, and 2.3 mg/m(2)/d every 28 days for a maximum of six(More)
Background Gefitinib potently inhibits neuroblastoma proliferation in vitro, and the gefitinib/irinotecan combination shows greater than additive activity against neuroblastoma xenografts. This Phase II pilot study estimated the rate of response to two courses of intravenous irinotecan plus oral gefitinib in children with untreated high-risk neuroblastoma.(More)
AIMS To determine the effect of dose and frequency of injection of Cu as Ca Cu EDTA on concentrations of Cu in liver, and the effect of a single 200 mg treatment on milk production and reproductive performance in New Zealand dairy cows. METHODS Four groups of dairy cows (n=18 per group) on three farms were injected with 100 or 200 mg Cu S/C once, or three(More)